One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study

Endocrine

Volumn 50, Issue 3, 2015, Pages 620-626

  Zavattaro, Marco ^a   Caputo, Marina ^a   Samà, Maria Teresa ^a   Mele, Chiara ^a   Chasseur, Luisa ^a   Marzullo, Paolo ^a,b   Pagano, Loredana ^a   Mauri, Maria Grazia ^a   Ponziani, Maria Chantal ^a   Aimaretti, Gianluca ^a   Prodam, Flavia ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Diabetes; Human; Kidney; Liraglutide

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; MIDDLE AGED;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84949109019     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0519-0     Document Type: Article

References (32)

1. M. Malm-Erjefält, I. Bjørnsdottir, J. Vanggaard, H. Helleberg, U. Larsen, B. Oosterhuis, Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab. Dispos. 38(11), 1944–1953 (2010)
2. J.A. Davidson, J. Brett, A. Falahati, D. Scott, Mild renal impairment and the efficacy and safety of liraglutide. Endocr. Pr. 17(3), 345–355 (2011)
3. D. Russell-Jones, The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int. J. Clin. Pract. 64(10), 1402–1414 (2010)
4. S. Madsbad, Liraglutide effect and action in diabetes (LEAD™) trials. Expert Rev. Endocrinol. Metab. 4(2), 119–129 (2009)
5. J.P. Gutzwiller, S. Tschopp, A. Bock, C.E. Zehnder, A.R. Huber, M. Kreyenbuehl et al., Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89(6), 3055–3061 (2004)
6. P. Schlatter, C. Beglinger, J. Drewe, H. Gutmann, Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul. Pept. 141(1–3), 120–128 (2007)
7. R.O. Crajoinas, F.T. Oricchio, T.D. Pessoa, B.P. Pacheco, L.M. Lessa, G. Malnic et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Ren. Physiol. 301(2), 355–363 (2011)
8. C. Moreno, M. Mistry, R.J. Roman, Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol. 434(3), 163–167 (2002)
9. T. Nyström, A.T. Gonon, A. Sjöholm, J. Pernow, Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 125(1–3), 173–177 (2005)
10. C.M. Florkowski, J.S. Chew-Harris, Methods of Estimating GFR - Different Equations Including CKD-EPI. Clin. Biochem. Rev. 32(2), 75–79 (2011)
11. A.S. Levey, L.A. Stevens, C.H. Schmid, Y. Zhang, A.F. Castro, H.I. Feldman et al., A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009)
12. M. Marre, J. Shaw, M. Brändle, W.M. Bebakar, N.A. Kamaruddin, J. Strand, M. Zdravkovic et al., LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26(3), 268–278 (2009)
13. J.J. Neumiller, T.E. Sonnett, L.D. Wood, S.M. Setter, R.K. Campbell, Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab. Syndr. Obes. 3, 215–226 (2010)
14. M. Rigato, G.P. Fadini, Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. 7, 107–120 (2014)
15. G. Aimaretti, Liraglutide: a once-daily human glucagon-like peptide-1 analogue. J. Endocrinol. Invest. 32(8), 701–703 (2009)
16. R.R. Henry, J.B. Buse, G. Sesti, M.J. Davies, K.H. Jensen, J. Brett et al., Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr. Pract. 17(6), 906–913 (2011)
17. K.Y. Thong, C. Walton, R. Ryder, Safety and efficacy of liraglutide 1.2 mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit. Prac. Diabetes J. 30(2), 71–76 (2013)
18. T. Vilsbøll, M. Zdravkovic, T. Le-Thi, T. Krarup, O. Schmitz, J.P. Courrèges et al., Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30(6), 1608–1610 (2007)
19. B. Wang, J. Zhong, H. Lin, Z. Zhao, Z. Yan, H. He, Y. Ni et al., Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15(8), 737–749 (2013)
20. L. E. Robinson, T. A. Holt, K. Rees, H. S. Randeva, J. P. O’Hare, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1), e001986 (2013). doi:10.1136/bmjopen-2012-001986
21. M. Katout, H. Zhu, J. Rutsky, P. Shah, R.D. Brook, J. Zhong et al., Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am. J. Hypertens. 27(1), 130–139 (2014)
22. K. Okada, K. Kotani, H. Yagyu, A. Ando, J. Osuga, S. Ishibashi, Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine 47(3), 962–964 (2014)
23. K. Hirata, S. Kume, S. Araki, M. Sakaguchi, M. Chin-Kanasaki, K. Isshiki et al., Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem. Biophys. Res. Commun. 380(1), 44–49 (2009)
24. P. Anagnostis, V.G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis, D.P. Mikhailidis, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes. Metab. 13(4), 302–312 (2011)
25. L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898–905 (2009)
26. C.B. Giorda, E. Nada, B. Tartaglino, Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46(3), 406–419 (2014)
27. W.J. Liu, S.H. Xie, Y.N. Liu, W. Kim, H.Y. Jin, S.K. Park et al., Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 340(2), 248–255 (2012)
28. H. Zhang, X. Zhang, C. Hu, W. Lu, Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res. 35(6), 483–488 (2012)
29. M. Haluzík, J. Frolík, I. Rychlík, Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int. J. Endocrinol. (2013). doi:10.1155/2013/895102
30. C. Pyke, R.S. Heller, R.K. Kirk, C. Orskov, S. Reedtz-Runge, P. Kaastrup et al., GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155(4), 1280–1290 (2014)
31. M.J. Lazzara, W.M. Deen, Model of albumin reabsorption in the proximal tubule. Am. J. Physiol. Renal. Physiol. 292(1), 430–439 (2007)
32. S.P. Marso, N.R. Poulter, S.E. Nissen, M.A. Nauck, B. Zinman, G.H. Daniels et al., Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am. Heart J. 166(5), 823–830 (2013)